Skip to search formSkip to main contentSkip to account menu

AN2690

Known as: AN 2690, AN-2690 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

tavaborole

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Antifungal activity and tautomeric cyclization equilibria of formylphenylboronic acids.
2018
2018
Leishmania donovani Parasites Are Inhibited by the Benzoxaborole AN2690 Targeting Leucyl-tRNA Synthetase
Visceral leishmaniasis is an important public health threat in parts of India. It is caused by a protozoan parasite, Leishmania… 
Review
2014
Review
2014
tRNAs as Antibiotic Targets
Transfer RNAs (tRNAs) are central players in the protein translation machinery and as such are prominent targets for a large… 
Review
2014
Review
2014
Tavaborole (AN-2690) for the treatment of onychomycosis of the toenail in adults
Onychomycosis is a challenging nail disease that is difficult to treat due to the thickness and impermeability of the nail plate… 
Highly Cited
2009
Highly Cited
2009
Crystal structures of the human and fungal cytosolic Leucyl-tRNA synthetase editing domains: A structural basis for the rational design of antifungal benzoxaboroles.
Highly Cited
2009
Highly Cited
2009
tRNA-dependent Pre-transfer Editing by Prokaryotic Leucyl-tRNA Synthetase*
To prevent genetic code ambiguity due to misincorporation of amino acids into proteins, aminoacyl-tRNA synthetases have evolved… 
Highly Cited
2007
Highly Cited
2007
In Vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate.
Onychomycosis is a challenging fungal infection to treat topically, likely due to the unique properties of the nail plate. This… 
Review
2007
Review
2007
Recent progress on the topical therapy of onychomycosis
Onychomycosis is a fungal infection of the fingernails and toenails that results in thickening, discoloration, splitting of the… 
Review
2007
Review
2007
AN-2690, a novel antifungal for the topical treatment of onychomycosis.
Schering-Plough Corp, under license from Anacor Pharmaceuticals Inc, is developing AN-2690, an antifungal agent with activity… 
Highly Cited
2006
Highly Cited
2006
Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis.
A structure-activity relationship investigation for a more efficacious therapy to treat onychomycosis, a fungal infection of the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)